UBS lowered the firm’s price target on Jasper Therapeutics (JSPR) to $33 from $38 and keeps a Buy rating on the shares. Following the Q1 earnings report, all eyes are on the upcoming updates on briquilimab in chronic inducible urticaria and chronic spontaneous urticaria, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Promising Advancements in Jasper Therapeutics’ Briquilimab Programs Highlight Market Potential
- Positive Outlook for Jasper Therapeutics: Promising Clinical Developments and Strategic Updates Support Buy Rating
- Jasper Therapeutics Faces Financial Challenges Amid Rising R&D Costs
- Jasper Therapeutics reports Q1 EPS ($1.41), consensus ($1.48)
- JSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue